These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23525357)

  • 1. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR
    Chaput N; Flament C; Locher C; Desbois M; Rey A; Rusakiewicz S; Poirier-Colame V; Pautier P; Le Cesne A; Soria JC; Paci A; Rosenzwajg M; Klatzmann D; Eggermont A; Robert C; Zitvogel L
    Oncoimmunology; 2013 Feb; 2(2):e23080. PubMed ID: 23525357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
    Pautier P; Locher C; Robert C; Deroussent A; Flament C; Le Cesne A; Rey A; Bahleda R; Ribrag V; Soria JC; Vassal G; Eggermont A; Zitvogel L; Chaput N; Paci A
    Oncoimmunology; 2013 Feb; 2(2):e23079. PubMed ID: 23525192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.
    Loyon R; Picard E; Mauvais O; Queiroz L; Mougey V; Pallandre JR; Galaine J; Mercier-Letondal P; Kellerman G; Chaput N; Wijdenes J; Adotévi O; Ferrand C; Romero P; Godet Y; Borg C
    J Immunol; 2016 Jul; 197(1):85-96. PubMed ID: 27233967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of immunophenotyping of peripheral lymphocytes in adult patients with infectious mononucleosis and chronic active Epstein-Barr virus infection].
    Xie J; Wang HL; Qiu ZF; Li TS
    Zhonghua Nei Ke Za Zhi; 2016 Jun; 55(6):455-9. PubMed ID: 27256608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
    Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
    PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
    Camisaschi C; Filipazzi P; Tazzari M; Casati C; Beretta V; Pilla L; Patuzzo R; Maurichi A; Cova A; Maio M; Chiarion-Sileni V; Tragni G; Santinami M; Vergani B; Villa A; Berti E; Umansky L; Beckhove P; Umansky V; Parmiani G; Rivoltini L; Castelli C
    Cancer Immunol Immunother; 2013 May; 62(5):897-908. PubMed ID: 23589107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
    Mirandola P; Ponti C; Gobbi G; Sponzilli I; Vaccarezza M; Cocco L; Zauli G; Secchiero P; Manzoli FA; Vitale M
    Blood; 2004 Oct; 104(8):2418-24. PubMed ID: 15205263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
    Curti BD; Ochoa AC; Powers GC; Kopp WC; Alvord WG; Janik JE; Gause BL; Dunn B; Kopreski MS; Fenton R; Zea A; Dansky-Ullmann C; Strobl S; Harvey L; Nelson E; Sznol M; Longo DL
    J Clin Oncol; 1998 Aug; 16(8):2752-60. PubMed ID: 9704728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.
    Costa-García M; Ataya M; Moraru M; Vilches C; López-Botet M; Muntasell A
    Front Immunol; 2019; 10():687. PubMed ID: 31001281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
    Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
    Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
    Frederiksen KS; Lundsgaard D; Freeman JA; Hughes SD; Holm TL; Skrumsager BK; Petri A; Hansen LT; McArthur GA; Davis ID; Skak K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1439-49. PubMed ID: 18286285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer.
    Takenoyama M; Yasumoto K; Harada M; Matsuzaki G; Ishida T; Sugimachi K; Nomoto K
    Immunobiology; 1996 Jul; 195(2):140-51. PubMed ID: 8877391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
    Ménard C; Blay JY; Borg C; Michiels S; Ghiringhelli F; Robert C; Nonn C; Chaput N; Taïeb J; Delahaye NF; Flament C; Emile JF; Le Cesne A; Zitvogel L
    Cancer Res; 2009 Apr; 69(8):3563-9. PubMed ID: 19351841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
    Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA
    Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.